The PCV24 vaccine developed by Reinovax with the implementation of an innovative design and manufacturing processes, showed excellent immunogenicity and safety profiles. Currently the phase II clinical trial for adults has been completed, and phase I trial for infants is expected to be finished in the first half of 2025.
-
01.Research Platform
Reinovax’s R&D center has a lab space of 2,200 square meters. It empowers the ability in various research technologies including gene engineering, cultivation and fermentation, separation and purification, bacterial polysaccharide technology, molecular coupling, immune evaluation, quality evaluation, adjuvant technology, and mRNA technology, which serves as a solid foundation for the R&D of novel vaccines and protein therapeutics.
-
02.Pilot-Scale Process Platform
A GMP-like pilot-scale manufacturing base with an area of 5,026 square meters was established in Lingang, Shanghai. The base encompasses pilot-scale process development, GMP-like pilot-scale manufacturing, filling system, QC laboratory, QA system, and various utility systems. It provides an indispensable platform for process optimization, IND application, and the preparation of clinical samples.
-
03.GMP Manufacturing Site
The commercial scale GMP manufacturing base located in Changchun city, compliant with WHO/EU standards, occupies a total area of approximately 78,700 square meters with the completed construction area of 77,600 square meters at the first stage. This site possesses the capacity of the complete GMP manufacturing from the cell bank to the finished product as well as the all supporting functional units such as quality system, utilities, warehouse, animal facility, waste management, and office building etc.
March 20, 2025, Shanghai — Shanghai Reinovax Biologics Co., Ltd. and its wholly subsidiary Changchun Reinovax Biologics Co., Ltd. (collectively called "Reinovax") ......
-
2024-10-23 Industry NewsThe Special Report of the "Ingenuity" Program on Reinovax Biologics -“Ingenious Cultivation，Innovative Vaccine” " Was Officially Broadcast on CCTV!
-
2024-04-26 Industry NewsReinovax Biologics Initiated Phase I Clinical Trial of 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Infants and Toddlers
-
2024-04-17 Industry NewsReinovax launched the Phase II clinical trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine in adults.
-
2023-11-21 Industry NewsReinovax launched the Phase I Clinical Trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Zhenjiang, Jiangsu province.
Reinovax WeChat official account
Friendship link: Changchun High-tech Group